Leon Moulder, Jr. Purchases 60,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. acquired 60,000 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were purchased at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the acquisition, the chief executive officer owned 96,928 shares of the company’s stock, valued at $1,636,144.64. This represents a 162.48% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zenas BioPharma Stock Up 5.5%

NASDAQ:ZBIO opened at $17.84 on Wednesday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94. The company has a market cap of $1.13 billion, a PE ratio of -2.11 and a beta of -0.61. Zenas BioPharma, Inc. has a 52-week low of $8.91 and a 52-week high of $44.60. The stock has a 50-day simple moving average of $20.89 and a 200 day simple moving average of $26.55.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same period in the prior year, the company earned ($0.80) EPS. On average, sell-side analysts expect that Zenas BioPharma, Inc. will post -4.47 EPS for the current fiscal year.

Trending Headlines about Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO Leon Moulder, Jr. bought 60,000 shares for about $1.01 million, a sizable insider purchase that signals management confidence in Zenas BioPharma’s outlook. Article Title
• Positive Sentiment: Zenas BioPharma announced an upcoming presentation of Phase 3 INDIGO trial results for obexelimab in IgG4-related disease at the EULAR 2026 Congress, which could serve as a near-term clinical catalyst if the data are well received. Article Title
• Neutral Sentiment: HC Wainwright kept a Buy rating and $44 price target on ZBIO, but lowered earnings estimates across several periods, including FY2026, FY2027, FY2028, FY2029, FY2030, and near-term quarters. The unchanged bullish rating helps, but the repeated estimate cuts point to softer expectations for profitability and can weigh on sentiment. Article Title
• Neutral Sentiment: The company also granted inducement RSUs to newly hired employees, a routine compensation move that is unlikely to be a major stock driver on its own. Article Title

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. SR One Capital Management LP lifted its stake in Zenas BioPharma by 2.6% in the 4th quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock valued at $182,924,000 after purchasing an additional 126,315 shares during the last quarter. NEA Management Company LLC raised its stake in Zenas BioPharma by 28.9% in the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after buying an additional 789,500 shares during the period. Federated Hermes Inc. raised its stake in Zenas BioPharma by 45.9% in the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after buying an additional 853,740 shares during the period. Vanguard Group Inc. raised its stake in Zenas BioPharma by 25.0% in the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after buying an additional 290,307 shares during the period. Finally, Polar Capital Holdings Plc bought a new stake in Zenas BioPharma in the fourth quarter valued at approximately $38,402,000.

Analysts Set New Price Targets

A number of research firms recently issued reports on ZBIO. HC Wainwright reiterated a “buy” rating and set a $44.00 price objective on shares of Zenas BioPharma in a report on Friday, May 15th. Citigroup reiterated a “buy” rating on shares of Zenas BioPharma in a report on Thursday, May 14th. Guggenheim increased their price objective on Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Friday, March 27th. Finally, Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.29.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.